Blood Concentration Monitoring of Vancomycin in One Patient with Peritoneal Dialysis-related Peritonitis

doi:10.19803/j.1672-8629.2019.11.09

Abstract

Abstract: Objective To provide reference for clinical pharmacists when participating in anti-infection therapy and individualized pharmaceutical care for patients with peritoneal dialysis-related peritonitis. Methods Clinical pharmacists participated in the pharmaceutical treatment of a patient with peritonitis in our hospital by consulting relevant information on diagnosis and treatment of peritonitis and monitoring blood drug concentration, and gave recommendations on the vancomycin medication regimen to assist clinicians in formulating an individualized regimen. Results After anti-infection therapy, the peritonitis of the patient was effectively controlled and no adverse drug reactions occurred. Conclusion Using blood concentration monitoring technology and relevant professional knowledge, clinical pharmacists can play an important role in the treatment of peritonitis patients by assisting clinicians in the preparation and modification of medication regimens, and by providing individualized pharmaceutical care for patients.Keywords: peritonitis; peritoneal dialysis; vancomycin; blood concentration monitoring

CLC Number:

R978.1

YANG Qing, CAI Ning, YUAN Ling, SUN Bin, JIN Xin. Blood Concentration Monitoring of Vancomycin in One Patient with Peritoneal Dialysis-related Peritonitis[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 683-687.

References

[1] Barretti P, Pereira Doles J V, Pinotti D G, et al. Evidence-based medicine: An update on treatments for peritonealdialysis-related peritonitis[J]. World J Nephrol, 2015, 4(2):287-294.
[2] 宋佳妮, 滕兰波. 腹膜透析相关性腹膜炎的研究进展[J].国际泌尿系统杂志, 2017, 37(1): 152-156.
[3] 赵雯, 刘伦志. 腹膜透析相关性腹膜炎的研究进展[J].世界最新医学信息文摘, 2019, 19(6): 85-88.
[4] 吴敏. 延续护理在持续性非卧床腹膜透析(CAPD)患者临床应用中的效果[J]. 世界最新医学信息文摘, 2018, 18(96): 238-241.
[5] Li P K, Szeto C C, Piraino B, et a1. ISPD Peritonitis Recommendations:2016 Update on Prevention and Treatment[J]. Petit Dial Int,2016, 36(5): 481-508.
[6] 温雯, 李月红. 2016年国际腹膜透析协会腹膜炎预防和治疗推荐指南解读[J]. 临床内科杂志, 2017, 34(1): 70-72.
[7] 陈佰仪, 管向东, 何礼贤, 等. 万古霉素临床应用中国专家共识(2011版)[J]. 中国新药与临床杂志, 2011, 30(8):561-573.
[8] Rybak M, Lomaestro B, Rotschafer J C, et al.Therapeuticmonitoring of vancomycin in adult patients: a consensusreview of the American Society of Health-System Pharmacists,the Infectious Diseases Society of America,and the Societyof Infectious Diseases Pharmacists[J]. Am J Health SystPharm, 2009, 66(10): 82-98.
[9] Ye Z K, Chen Y L, Chen K, et al.Therapeutic drug monitoringof vancomycin: a guideline of the Division of TherapeuticDrug Monitoring, Chinese Pharmacological Society[J].J Antimicrob Chemother, 2016,71(11):3020-3025.
[10] 杨洋, 吴湜, 郭燕, 等. 血液分离利奈唑胺耐药头状葡萄球菌耐药性及相关临床特征分析[J]. 中国感染与化疗杂志, 2017, 17(4): 382-386.
[11] 冯洁仪, 邓述欢, 赖少芬, 等. 头状葡萄球菌在临床感染的分布状况和耐药分析[J]. 检验医学与临床, 2019, 16(1):109-111.
[12] 白向荣, 褚燕琦. 临床药师在干预万古霉素血药浓度监测的作用研究[J]. 中国药物警戒, 2015, 12(7): 439-443.
[13] 经力, 刘滔滔, 郭晴, 等. 万古霉素群体药代动力学模型在不同人群中的预测性能[J]. 中国临床药理学杂志, 2019,35(6): 577-580.
[14] 杨平, 刘亚欧, 时正媛, 等. 万古霉素在重症监护患者的群体药代动力学模型建立与验证[J]. 中国临床药理学杂志, 2018, 34(6): 656-659.
[15] 庞惠媚, 刘滔滔, 韦文兴, 等. 万古霉素群体药代动力学模型在临床应用中的预测性能的评估[J]. 中国临床药理学杂志, 2018, 34(6): 710-724.